Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation?

Nucl Med Biol. 1998 Aug;25(6):539-41. Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation? Leitha T1, Glaser C, Lang S. Abstract A consensus has emerged that early imaging (within 20 min post-injection [p.i.] of sestamibi) has the highest diagnostic yield. Tc-99m-sestamibi uptake has been associated with P-glycoprotein-mediated multi-drug resistance […]